Cirmtuzumab could work synergistically with the Bruton tyrosine kinase inhibitor ibrutinib to treat patients with CLL or other ROR1+ B‐cell malignancies.412. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.